Showing results (681-690 of 727) with videos related to
Sort By:
Pageof 73
Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2014
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Daniel Morgensztern, Meghan J Campo, Suzanne E Dahlberg, et al.The New England Journal of Medicine|September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancerAlice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.JTO Clinical and Research Reports|October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or CemiplimabBiagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.The Lancet. Oncology|September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.Biorxiv : the Preprint Server for Biology|December 11, 2023
A (Sub)field Guide to Quality Control in Hippocampal Subfield Segmentation on Highresolution T2-weighted MRIK L Canada, N Mazloum-Farzaghi, G Rådman, et al.Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.Pageof 73